Siegfried Holding H1 profit misses on drug products weakness, guidance held

Siegfried Holding AG reported mixed first-half 2025 results, with its high-margin Drug Products division revenue missing consensus by 3% at CHF206 million and net profit falling short, primarily due to CHF10 million in destocking and currency headwinds. Despite these pressures, overall group revenue of CHF620 million was broadly in line with expectations, and adjusted EBITDA matched consensus at CHF134 million, yielding an improved margin of 21.6%. The company confirmed its full-year 2025 and medium-term guidance, anticipating a stronger second half and highlighting strategic capacity expansions in ophthalmics and pre-filled syringes coming online from 2026.

Analysis

Siegfried Holding AG (SFZN) presented mixed first-half 2025 results, characterized by a shortfall in its high-margin Drug Products division and a net profit miss, which overshadowed an in-line adjusted EBITDA. Group revenue of CHF620 million slightly missed the CHF625 million consensus, primarily due to the Drug Products segment's sales of CHF206 million, which were 3% below expectations. This underperformance is significant as analysts highlight this division as a key driver of profitability. Consequently, net profit of CHF65.7 million fell short of the anticipated CHF72 million. Management attributed the weakness to approximately CHF10 million in destocking and currency headwinds, leading to a back-half weighted performance outlook. Despite these pressures, adjusted EBITDA met consensus at CHF134 million, yielding a margin of 21.6% that narrowly beat the 21.4% forecast, aided by stable administrative expenses. Crucially, the company reaffirmed its full-year 2025 guidance for mid-single-digit revenue growth and an adjusted EBITDA margin above 22%, signaling strong confidence in a second-half recovery. This outlook is further supported by a pipeline of strategic capacity expansions in ophthalmics and pre-filled syringes, which are slated to contribute to revenue starting in 2026 and 2027.

Key Decisions for Investors

• Investors should closely monitor the company's execution in the second half of 2025, as achieving the confirmed full-year guidance now depends heavily on a significant recovery from the destocking and currency headwinds seen in H1.
• The underperformance of the high-margin Drug Products division is a key risk; future earnings reports should be scrutinized for a rebound in this segment, as its performance is critical to realizing the company's target of an EBITDA margin above 22%.
• For long-term investors, the current weakness may present an opportunity, given that management has maintained its medium-term outlook and has clear growth catalysts from capacity expansions in ophthalmics and pre-filled syringes expected to come online in 2026-2027.